论文部分内容阅读
目的评价门冬胰岛素联合地特胰岛素与胰岛素泵持续皮下输注对新诊断T2DM患者的有效性和安全性。方法 94例新诊断的T2DM患者分别使用门冬胰岛素联合地特胰岛素(A组)和胰岛素泵持续皮下输注(B组)强化治疗方案,观察治疗前后的FPG、2hPG、FC-P、2hC-P、血糖达标时间、达标时胰岛素用量及低血糖发生率。结果治疗2周后,两组FPG、2hPG均较基线显著降低,而血糖达标时间、达标时胰岛素用量、低血糖发生率差异无统计学意义;两组FC-P治疗前为(0.69±0.13)、(0.81±0.15),治疗后为(1.3±0.2),(1.50±0.15),2hC-P治疗前为(1.62±0.16)、(1.44±0.17),治疗后为(3.80±0.80),(3.50±1.21),治疗前后差异均有统计学意义(P均<0.05)。结论对于新诊断的T2DM患者,与胰岛素泵持续皮下输注方案比较,门冬胰岛素联合地特胰岛素可安全、有效地控制血糖,恢复胰岛β细胞功能。
Objective To evaluate the efficacy and safety of continuous insulin infusion of insulin aspart and insulin pump in newly diagnosed T2DM patients. Methods Ninety-four patients with newly diagnosed T2DM were treated with insulin aspart insulin plus insulin (group A) and insulin pump (subcutaneous infusion) (group B). The levels of FPG, 2hPG, FC-P and 2hC- P, blood glucose compliance time, insulin dosage and the incidence of hypoglycemia. Results After 2 weeks of treatment, FPG and 2hPG in both groups were significantly lower than those in baseline. However, there were no significant differences in the time of reaching the standard of glycemic control, the insulin dosage and the incidence of hypoglycemia at the time of reaching the standard. The FC-P before treatment was (0.69 ± 0.13) (1.81 ± 0.16) and (1.44 ± 0.17) before treatment and (3.80 ± 0.80) and (1.80 ± 0.80) after treatment 3.50 ± 1.21), the difference was statistically significant before and after treatment (all P <0.05). Conclusions Aspartate insulin and insulin detemir insulin can safely and effectively control blood glucose and restore islet β-cell function in newly diagnosed T2DM patients compared with continuous subcutaneous infusion with insulin pump.